Media contact: Brianna Hoge, bhoge@uab.edu
Steve Rowe, M.D.
Marnix E. Heersink School of Medicine
Division of Pulmonary, Allergy and Critical Care Medicine
Areas of expertise:
- Cystic fibrosis
- Effects of cigarettes and vaping
- COPD
Rowe specializes in developing new treatments for cystic fibrosis, the most common autosomal recessive genetic disease, and the cause of severe pulmonary disease affecting children and young adults. He founded the CF Transition Clinic for adolescents and young adults with the disease. He maintains expertise in the design and conduct of clinical trials targeting the basic CF defect.
Rowe also has an interest in biomarkers of CF and other related airway diseases including measures of ion transport and the relation between mucus stasis and inflammation. He currently directs a clinical research program that examines the relationship between CF and the chronic bronchitis of COPD.
Media appearances:
- ‘We’re still waiting’: As cystic fibrosis drugs deliver new hope, not everyone is being swept up by scientific progress, STAT
- Teen Use of Flavored Tobacco Was Down, But E-Cigarettes Are Bringing It Back Up, Healthline
- Addicted for life’: A surge of vaping among teens alarms Alabama, AL.com
- 'We conquered a diseas': How vertex delievered a transformative medicine for cystic fibrosis, STAT
- FDA approves TRIKAFTA to treat the underlying cause of cystic fibrosis in specific instances for people ages 12 and older, Business Wire